- Home
- SUI vs UTHR Comparison
SUI vs UTHR Comparison
Compare SUI & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUI
- UTHR
- Stock Information
- Founded
- SUI 1975
- UTHR 1996
- Country
- SUI United States
- UTHR United States
- Employees
- SUI N/A
- UTHR N/A
- Industry
- SUI Real Estate Investment Trusts
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- SUI Real Estate
- UTHR Health Care
- Exchange
- SUI Nasdaq
- UTHR Nasdaq
- Market Cap
- SUI 16.0B
- UTHR 14.4B
- IPO Year
- SUI 1993
- UTHR 1999
- Fundamental
- Price
- SUI $125.23
- UTHR $297.02
- Analyst Decision
- SUI Buy
- UTHR Buy
- Analyst Count
- SUI 13
- UTHR 13
- Target Price
- SUI $138.08
- UTHR $383.08
- AVG Volume (30 Days)
- SUI 912.9K
- UTHR 561.1K
- Earning Date
- SUI 07-30-2025
- UTHR 07-30-2025
- Dividend Yield
- SUI 3.30%
- UTHR N/A
- EPS Growth
- SUI N/A
- UTHR 18.86
- EPS
- SUI 0.58
- UTHR 25.10
- Revenue
- SUI $3,193,300,000.00
- UTHR $2,994,100,000.00
- Revenue This Year
- SUI N/A
- UTHR $14.58
- Revenue Next Year
- SUI $2.04
- UTHR $6.34
- P/E Ratio
- SUI $154.73
- UTHR $11.77
- Revenue Growth
- SUI 6.74
- UTHR 19.84
- 52 Week Low
- SUI $109.22
- UTHR $266.98
- 52 Week High
- SUI $147.83
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- SUI 47.07
- UTHR 51.32
- Support Level
- SUI $124.44
- UTHR $286.68
- Resistance Level
- SUI $128.57
- UTHR $301.75
- Average True Range (ATR)
- SUI 2.49
- UTHR 6.73
- MACD
- SUI -0.27
- UTHR 1.81
- Stochastic Oscillator
- SUI 19.46
- UTHR 77.16
About SUI Sun Communities Inc.
Sun Communities is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently owns a portfolio of 645 properties, which includes 341 manufactured housing communities, 166 residential vehicle communities, and 138 marina properties. Sun targets owning properties that are desirable as second homes or vacation properties with nearly 50% of the portfolio located in either Florida or Michigan near major bodies of water.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.